Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they or their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol.~* Healthy Chinese females between and including 9 and 17 years of age at the time of the first vaccination.~* Written informed consent obtained from the parent(s)/LAR(s) of the subject and informed assent obtained from the subject, if appropriate, prior to enrolment.~* Healthy subjects as established by medical history and history-directed clinical examination before entering into the study.~* Subjects must not be pregnant. Absence of pregnancy will be verified with a urine pregnancy test before each vaccination.~* Subjects must be either of non-childbearing potential, or if of childbearing potential, they must be abstinent or have practiced adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and agree to continue such precautions for 2 months after completion of the vaccination series.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after (i.e., Days 0-29) the first dose of vaccine.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* A subject planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the study period and up to two months after the last vaccine dose.~* Pregnant or breastfeeding. Subjects must be at least three months post-pregnancy and not breastfeeding to enter the study.~* Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the protocol during the study period.~* Previous administration of components of the study vaccine.~* History of chronic condition(s) requiring treatment such as cancer or autoimmune disease.~* History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the vaccine.~* Hypersensitivity to latex.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.

- Gender: FEMALE
- Minimum Age: 9 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Cervarix Group (Type: EXPERIMENTAL): Subjects received 3 doses of Cervarix vaccine. Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
- Placebo Group (Type: EXPERIMENTAL): Subjects received 3 doses of placebo. Placebo vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete